Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.